- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Revelation Biosciences vergibt gesperrte Aktienpakete an CEO und CFO | 1 | Investing.com Deutsch | ||
| 19.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.08. | Revelation Biosciences mandatiert Avance Clinical für Phase-2/3-Studie bei akuter Nierenschädigung | 1 | Investing.com Deutsch | ||
| 19.08. | Revelation Biosciences selects CRO for phase 2/3 AKI study | 1 | Investing.com | ||
| 07.08. | Revelation Biosciences GAAP EPS of -$0.87 | 1 | Seeking Alpha | ||
| 06.08. | Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 | 493 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions... ► Artikel lesen | |
| 06.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 03.08. | Revelation Biosciences, Inc.: Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury | 405 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions... ► Artikel lesen | |
| 21.07. | Revelation Biosciences, Inc.: Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 373 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 13.07. | REVELATION BIOSCIENCES, INC. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 13.07. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights Plan | 547 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 24.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Revelation Biosciences, Inc.: Revelation Biosciences Expands Acute Kidney Injury Advisory Board | 297 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 11.05. | Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders | 683 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 08.05. | Revelation Biosciences GAAP EPS of -$2.71 | 2 | Seeking Alpha | ||
| 07.05. | Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 | 455 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 07.05. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 1,450 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,196 | -2,14 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| CEL-SCI | 1,840 | -8,00 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,447 | +1,13 % | Moleculin Biotech, Inc.: Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit | ||
| PDS BIOTECHNOLOGY | 1,190 | -4,03 % | PDS Biotechnology Corp - 8-K, Current Report | ||
| LISATA THERAPEUTICS | 0,935 | 0,00 % | Lisata Therapeutics, Inc.: Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly | Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks... ► Artikel lesen | |
| GEOVAX LABS | 0,285 | +1,25 % | EQS-News: GeoVax, Inc.: GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 06.10.2026 / 14:37... ► Artikel lesen | |
| COCRYSTAL | 0,925 | +1,09 % | H.C. Wainwright reiterates Cocrystal Pharma stock rating at buy | ||
| GOSSAMER BIO | 8,216 | 0,00 % | XFRA 4GB0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DECOY THERAPEUTICS | 1,470 | 0,00 % | Decoy Therapeutics Inc. - S-1, General form for registration of securities | ||
| JASPER THERAPEUTICS | 0,570 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants | REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 1,370 | -0,72 % | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | ||
| VISTAGEN THERAPEUTICS | 0,236 | 0,00 % | Vistagen Therapeutics, Inc. - 8-K, Current Report | ||
| IN8BIO | 1,170 | -4,10 % | IN8bio, Inc: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| METAVIA | 1,410 | 0,00 % | MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction | Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support... ► Artikel lesen |
REVELATION BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,01 % bei einem Aktienkurs von 0,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.